Literature DB >> 4357095

Pseudomonas cepacia tricuspid endocarditis: treatment with trimethoprim, sulfonamide, and polymyxin B.

J J Rahal, M S Simberkoff, P J Hyams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4357095     DOI: 10.1093/infdis/128.supplement_3.s762

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  7 in total

Review 1.  Principles of combination therapy.

Authors:  S Levin; A A Harris
Journal:  Bull N Y Acad Med       Date:  1975-10

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  A Unique Case of Burkholderia cepacia Prosthetic Mitral Valve Endocarditis and Literature Review.

Authors:  Laura E Dellalana; Kelly C Byrge; Jocelyn S Gandelman; Tara Lines; David M Aronoff; Anna K Person
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2019-05

4.  Sensitivity of different Pseudomonas species and Aeromonas hydrophila to trimethoprim and sulfamethoxazole separately and in combination.

Authors:  C E Nord; T Wadström; B Wretlind
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

5.  Spontaneous septic arthritis caused by Burkholderia cepacia.

Authors:  Roberto Augusto Miki; Lee Eric Rubin; Jessica Kirk; Seth D Dodds
Journal:  Iowa Orthop J       Date:  2006

6.  A case of native valve endocarditis caused by Burkholderia cepacia without predisposing factors.

Authors:  Hyun Kyun Ki; Sung Hea Kim; Seong Woo Han; Hae Suk Cheong
Journal:  BMC Infect Dis       Date:  2011-05-08       Impact factor: 3.090

Review 7.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.